Veru up on positive poxviruses therapy data from preclinical study

Veru

11/04/2023 17:47

** Shares of drug developer Veru Inc  VERU.O  rise 2% to ~$1
    ** Co reports positive data from a pre-clinical, test tube
study, testing effects of its experimental therapy, sabizabulin,
against a type of poxvirus 
    ** Poxviruses are a group of large DNA viruses that cause
smallpox and similar infectious diseases
    ** Sabizabulin prevented the release of poxvirus from
infected cells as well as their transfer to healthy cells in the
study, according to co
    ** Co adds that study data supports program expansion into
additional lethal smallpox treatment indications or other
related infections 
    ** VERU plans pre-investigational New Drug (IND) meeting
with FDA to evaluate sabizabulin under the Animal Rule
regulatory pathway for treatment of smallpox virus outbreak
    ** Including session's gain, co's stock down 80.7% YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))